Results 141 to 150 of about 39,211 (299)

Incorporating Pharmacogenomics into Cancer Therapy

, 2009
Heritable variations in genes associated with drug disposition and effects (i.e., drug metabolism, transport, and therapeutic target) contribute to individual heterogeneity in drug treatment response and tolerance.
Lee, Wooin, Lockhart, A. Craig, A. Craig Lockhart, Wooin Lee   +3 more
core   +1 more source

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

Brain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo, Marina De Miguel, Leire Extramiana, Mercedes Lachén‐Montes, Silvia Romero‐Murillo, Djordje Gveric, Joaquín Fernández‐Irigoyen, Enrique Santamaría   +7 more
wiley   +1 more source

Targeting hexokinase 2 to induce breast cancer cell senescence

British Journal of Pharmacology, EarlyView.
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof, Katarina Cisarova, Sandra Burgstaller, Mia Schwerer, Markus Absenger‐Novak, Philipp J. Jost, Roland Malli, Wolfgang F. Graier, Robert Lukowski   +8 more
wiley   +1 more source

Pharmacogenomics arrives.

Genome biology, 2004
We've had the human genome sequence for a little while now, and it looks as though we're still some way off being able to exclude from most clinical trials those people who will probably suffer side effects.
openaire   +2 more sources

Pharmacogenomics: Methods and Protocol

, 2006
Pharmacogenomics: Methods and ...
Dep Farmaceutische wetenschappen, Population-based studies of drug treatment: from molecule to patient outcomes, de Boer, A.   +2 more
core  

Plasma EC90 multiples are drug, target site and species specific—A physiologically based pharmacokinetic modelling example of nirmatrelvir central nervous system distribution

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Achieving minimum unbound drug concentration in plasma above in vitro EC90 is a common antiviral pharmacokinetic/pharmacodynamic (PK/PD) target. However, it often overlooks restricted distribution into target sites like the central nervous system (CNS), where a trough concentration above 1 × EC90 is needed.
Daan W. van Valkengoed, Xuanlin Liu, Sean N. Avedissian, Courtney V. Fletcher, Ashley N. Brown, Elizabeth C. M. de Lange, Anne‐Grete Märtson   +6 more
wiley   +1 more source

Biomimetic fusion nanosystem from ginger exosomes and tumor cell membranes: boosting PLK1-targeted therapy in BRCA-heterogeneous HGSOC

Journal of Nanobiotechnology
High-grade serous ovarian carcinoma (HGSOC) remains a lethal malignancy with few effective therapeutic options. In this study, we systematically evaluated the anti-tumor effect of Bi2536, an inhibitor of Polo-like kinase 1 (PLK1), in HGSOC, and clarified
Xue Zhou, Yutang Huang, Chenyi Li, Wenlu Mo, Weifeng Xia, Ruiqin Du, Lanxiang Wu, Hongbo Zhao   +7 more
doaj   +1 more source

Machine Learning‐Derived Immune Gene Signature Predicts Prognosis and Therapeutic Vulnerabilities in Multiple Myeloma

Cancer Science, EarlyView.
An immune‐related 12‐gene signature developed through integrative machine learning stratified overall survival across multiple myeloma cohorts and remained independently associated with outcome. Single‐cell, somatic mutation, and transcriptome‐based drug‐response analyses further linked the signature to multicellular bone marrow context, distinct ...
Kai Wang, Chenfei Zhao, Jingru Shi, Shiwei Liu, Yi Chen, Jujuan Wang, Zhengxu Sun, Sanmei Wang, Lei Fan, Jin Fan, Xiaoyan Qu   +10 more
wiley   +1 more source

Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice

Human Genomics
Background Community pharmacists must be well-equipped to advance pharmacogenomics services. Nevertheless, limited data is available regarding pharmacists' knowledge and attitudes toward pharmacogenomics testing.
Azza Ramadan, Anan S. Jarab, Ahmad Z. Al Meslamani   +2 more
doaj   +1 more source

Pharmacogenomics in Practice [PDF]

Clinical Pharmacology & Therapeutics, 2019
Wang, Liewei, Weinshilboum, Richard
openaire   +2 more sources